首页> 外国专利> METHODS AND COMPOSITIONS FOR INFUSION OF TRANSIENTLY ENGRAFTING, SELECTED POPULATIONS OF ALLOGENEIC LYMPHOCYTES TO TREAT CANCER

METHODS AND COMPOSITIONS FOR INFUSION OF TRANSIENTLY ENGRAFTING, SELECTED POPULATIONS OF ALLOGENEIC LYMPHOCYTES TO TREAT CANCER

机译:向癌症中瞬时转移同种异体淋巴细胞选择种群的方法和组合物

摘要

The invention provides methods and compositions for administration of allogeneic lymphocytes as an exogenous source of CD4+ T cell help for endogenous, tumor-reactive CD8+ T cells. Depletion of CD8+ T cells from the donor lymphocyte infusion reduces the risk of sustained engraftment and graft-versus-host disease. Removal of regulatory T cells from the infused population may augment the ability of non-regulatory T cells to provide help for endogenous effectors of anti-tumor immunity. Allogeneic T cell therapy is typically given in the context of allogeneic stem cell transplantation, in which the patient receives highly immunosuppressive conditioning followed by an infusion of a stem cell graft containing unselected populations of mature T cells. In the treatment described here, the graft is engineered to minimize the possibility of sustained donor cell engraftment, and the anti-tumor effector T cells derive from the host.
机译:本发明提供了用于施用同种异体淋巴细胞作为内源性,肿瘤反应性CD8 + T细胞的CD4 + T细胞帮助的外源来源的方法和组合物。从供体淋巴细胞输注中耗尽CD8 + T细胞可降低持续移植和移植物抗宿主疾病的风险。从注入的群体中去除调节性T细胞可以增强非调节性T细胞为内源性抗肿瘤免疫效应子提供帮助的能力。同种异体T细胞疗法通常是在同种异体干细胞移植的背景下进行的,其中患者接受高度免疫抑制条件,然后输注含有未选择的成熟T细胞群体的干细胞移植物。在此处描述的治疗方法中,对移植物进行了工程设计,以最大程度地减少供体细胞持续移植的可能性,并且抗肿瘤效应T细胞来源于宿主。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号